University of Exeter

The University of Exeter is launching a new postgraduate program on psychedelics, called "Psychedelics: Mind, Medicine, and Culture." The program aims to train therapists, mental health advocates, and healthcare workers on how to safely work with psilocybin, LSD, MDMA, and other...

The research partnership between UK-based psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) and the University of Exeter for an upcoming Phase 3 clinical trial has now formalized the study’s design, budget and the company’s contribution of about $1 million (GBP £...

Awakn Life Sciences Corp. (OTCQB: AWKNF), a revenue-generating biotech company researching, developing and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced that its upcoming Phase 3 clinical trial assessing ketamine-assisted therapy for...